StockData

Drugs Made In America Acquisition Corp. (DMAA) stock

DMAANasdaqBlank ChecksFiscal year ends December 31Also trades as DMAAR, DMAAU
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$10.90+0.00 (0.00%)

Close on Nov 17, 2026Market cap $264.62MP/E –Yield –

Drugs Made In America Acquisition operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Drugs Made In America Acquisition's operating cash flow for the twelve months ending Jun 30, 2026 was -$517.15K. For fiscal 2025 it was -$539.19K.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$539.19K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$244.61K–
Q1 FY2026Mar 31, 2026-$91.25K–
Q4 FY2025Dec 31, 2025-$125.18K–
Q3 FY2025Sep 30, 2025-$56.11K–
Q2 FY2025Jun 30, 2025-$106.66K–
Q1 FY2025Mar 31, 2025-$251.24K–

More Drugs Made In America Acquisition figures

See a number that looks wrong?